Ladies and gentlemen, thank you for standing by and welcome to the Third Quarter 2021 Medical Properties Trust Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, . Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would now like to turn the conference over to your host today, Charles Lambert. Thank you. Please go ahead.

Thank you. Good morning and welcome to the Medical Properties Trust conference call to discuss our third quarter 2021 financial results. With me today are Edward K. Aldag, Jr. Chairman, President and Chief Executive Officer of the Company. And Steven Hamner, Executive Vice President and Chief Financial Officer. Our press release was distributed this morning and furnished on Form 8-K with the Securities and Exchange Commission. If you did not receive a copy, it is available on our website at www.medicalpropertiestrust.com in the Investor Relations section. Additionally, we are hosting a live webcast of today's call, which you can access in that same section. During the course of this call, we will make projections and certain other statements that may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our financial results and future events to differ materially from those expressed in the underlying such forward-looking statements. We refer you to the Company's reports filed with the Securities and Exchange Commission for discussion of the factors that could cause the Company's actual results or future events to differ materially from those expressed in this call. The information being provided today is as of this date only and except as required by the federal securities laws, the Company does not undertake a duty to update any such information. In addition, during the course of the conference call, we will describe certain non-GAAP financial measures which should be considered in addition to and not in lieu of comparable GAAP financial measures. Please note that in our press release, Medical Properties Trust has reconciled all non-GAAP financial measures to the most directly comparable GAAP measures in accordance with Reg. G requirements. You can also refer to our website at www.medicalpropertiestrust.com for the most directly comparable financial measures and related reconciliations. I will now turn the call over to Chief Executive Officer, Ed Aldag. Edward K. Aldag, Jr: Thank you, Charles, and thanks all of you for listening in today for our third quarter 2021 earnings call. During the month of September, we made two announcements that are significant milestones for MPT. Steve will go over each of these in detail in a few moments. But it is important for me to put them in context. The first one was a partnership with Macquarie Infrastructure Partners V for eight Stuart hospitals in Massachusetts. These transactions alone reflect a number of very strong points. MBC is always referred to in all of our hospitals as important parts of any community’s infrastructure. As part of our underwriting, we investigate the importance of each facility to that specific community. As most of you know, Macquarie is one of the world's leading infrastructure investors. They too believe the premise that most hospital are an important part of our communities’ infrastructure. We regard research the world's leading experts in hospital investing. They turned to NBT in the words of one of their executives, NBT is the clear leader and there really isn't a number two, when we purchased the Massachusetts hospitals five-years ago. The cap rate on these leases was in the mid-7% range and is escalated since then, the value of these hospitals that we agreed with Macquarie was based on a market cap rate in the mid-5 percent range, reflecting our unique underwriting expertise. Stewards, operating skills and a market for hospital real estate that is rapidly attracting sophisticated private investors. These conditions establish a whole new value for our entire portfolio, not just the Massachusetts hospitals. We are excited about this relationship with Macquarie and we hope to be able to grow it together. And while we're not making any additional announcements today, we are encouraged about opportunities we have seen for similar relationships with other institutional investors in other markets. The next announcement is the pending acquisition by HCA of the operations of the Steward Utah hospitals. Steward acquired these hospitals in an MPT financed acquisition as a part of its acquisition Iasis in 2017. Over the last 4 years, Steward has done an outstanding job of growing the top and bottom lines for these facilities as a part of its transaction with Steward, HCA has agreed to enter into a new master lease with NBT for these facilities paying the same rent and annual escalators for the real estate as Steward is currently paying. Like the Macquarie transaction, this transaction provided reinforcement on the value of MPT's real estate by sophisticated third-parties along with the validation of the strong performance of these Stuart hospitals upon the closing of these two transactions, stewards concentration for MPT will have been reduced to approximately 18%. More importantly, no standalone Stuart regional market will represent more than 6% and no single Stuart operated property will represent more than 2% of our pro forma assets. Our largest single investment, approximating 3% of our assets, will then be operated by HCA. In 2019, the last year before the pandemic, MPT's acquisitions totaled approximately $4.5 billion in 2020 during the heart of the pandemic, NBT's acquisitions totaled approximately $3.6 billion, and year-to-date in 2021, we have acquired approximately $3.7 billion of additional investments. We have done this with the strategic use of JV capital, common equity through underwritten offerings in the ATM, selective dispositions, funds received from opportunistic debt repayments to MPT, Debt offerings with historic low interest rates and retention of earnings by the virtue of a very prudent AFFO dividend payout ratio. We continue to have a robust pipeline that we will execute selectively while effectively utilizing the most efficient sources of capital. Before speaking to the operator performance, I'd like to mention a special award that speaks to the importance MPT places on corporate culture. As we announced in late September, NBT ranges that fifth Best Place to Work for millennial's according to Modern Health care's Best Places Award, 2021. This was based on an employee survey conducted by an independent third-party, in which our overall employee engagement score of 98% was recorded. And in which particularly strong marks related to employee satisfaction and confidence in management were communicated by our employees across-the-board. Our most important asset is our people. And we are proud that our employee base is satisfied across multiple measures of our internal social responsibility. As NBT has grown over the years, we have attempted to show the performance of our portfolio in a number of ways. Many years back, we instituted a same-store analysis. When we were growing so fast and our total assets were much smaller than they are now, this approach made more sense. It was structured to show performance without undue influence from the newly acquired facilities. As we've gotten much larger, both in terms of total assets in dollars and in number of facilities. The accumulation of additional properties in any one period no longer creates the spikes up or down that could be misleading. We have therefore decided from this point forward that we will report total portfolio without regard to wind facilities are acquired, but these statistics will still exclude facilities where: A. No detailed individual hospital operating statistics are required under the lease. Now it's important to point out that each of these leases do provide overall information on the parent Company or aggregated hospital performance. This can include leases we inherited or master leases guaranteed, or master or guaranteed leases with investment-grade tenants such as UCL, Ashner, Ramsey, and a few others. There are approximately 80 facilities in this category. Or be our facilities that are so new to our portfolio, they're reporting part requirements have not yet begun, like Prairie and Springstone. There are approximately 70 facilities in this category, or C facilities that are under development. There currently only two facilities in this category. Our tenants result for the past 12 months are very strong. These results include the brands, but not the advances that were received about our hospital operators. For the past 12 months, our acute care hospital portfolio generated an EBITDARM coverage of slightly more than 3 times. The LTACH segment generated an EBITDARM coverage of more than 3 and 1/4 times. And the IRF coverage for the trailing 12 months was approximately 2.15 times. Now, since specific updates on some of our largest operators. Circle, which represents 11% of our portfolio, continues to show strong coverages. Their coverages for the second quarter in 2021 was substantially more than it was in the fourth quarter of 2020, which was also a strong quarter. Circle continues to have a strong liquidity position. And as a reminder, the American Insurance Company Centene, which already owned interest in Circle is now 100% owner of Circle. Ernest, which represents 3% of our portfolio, continues to perform at the very top of the market. Their coverages for both their herbs and LTACH are approaching 3 times. Like Circle, they too have a very strong liquidity position. Healthscope, which represents 5% of our portfolio, is seeing some of its best EBITDARM coverages since our acquisition of these facilities in June of 2019. LifePoint, which represents 5% of our portfolio, continues to outperform. Their EBITDARM continued to be one of the highest in our portfolio, and grew significantly from the first quarter to the second quarter on a trailing 12-month basis. LifePoint has a very strong liquidity position. And as a side note for LifePoint, some of you may have seen their announcement this week that after the Kindred acquisition, LifePoint will split the Company into two separate companies. We will have facilities with both companies and we have worked very close with LifePoint to ensure that MPT will retain its strong position within both of these companies. MEDIAN, which represents 5% of our portfolio continues its rock steady performance. MEDIAN performed superbly throughout the pandemic and continues along that path today. Their liquidity position also remains very strong. Prime, which represents 5% of our portfolio, continues its stellar performance. Their EBITDARM coverages at the very top of our portfolio. Prime has one of the strongest liquidity positions of any of our operators. On a very important additional note, St. Michael's Hospital in Newark, New Jersey, operated by Prime Healthcare, was rated the number 2 most socially responsible Hospital in America by Lown Institute Hospitals Index based on measures related to health outcomes, value, and equity. This is an addition to Prime itself, being ranked as the most socially responsible hospital operator in the U.S. We're proud of what our facilities and our operators mean to the communities they serve. Prairie, which represents 5% of our portfolio, reports that their operations continue to improve from 2020. They have experienced some labor issues in a few of their locations, but it is not a Company-wide issue. Our underwriting showed a 2020 EBITDARM coverage of approximately 2 times. Management reports, thus far, indicated that a coverage for 2021, generally in line with this number, will begin getting detailed reports from Prairie in the near future. Prospect, which reports -- which represent 7% of our portfolio, is showing its best EBITDARM coverage to-date. Their liquidity too remains very strong. Steward, which pro forma represents 8% of our portfolio is generating its strongest EBITDARM coverage is to-date well in excess of 2.5 times. I would also like to point out Steward received recognition for ranking first in membership, tied for first in quality and earned the second highest shared savings payout of 513 participants in the CMS Medicare Shared Savings Program. As the nation's largest position-lead healthcare network and accountable care organization, Steward generated more than $68 million in total 2020 Medicare cost savings while receiving a perfect 100% quality rating amid the challenging challenges of COVID-19 global pandemic. All across the board, our operators continue to perform with outstanding results. In some general news, regarding operations across our various regions, our domestic operators saw volumes rebound in the first half of 2020 to 2019 numbers. In Europe, private hospital systems are increasingly viewed as solutions for backlogs of elective procedures caused by the pandemic. Patient volumes continue to normalize there as operations continue to perform well. In Australia, 70% of eligible citizens are now fully vaccinated, triggering Phase 2 of Australia's reopening. Most of Australia expects to be fully opened by the end of this year. Most hospitals are currently operating at normal levels. In Colombia, occupancy rates to remain high and surgeries have increased substantially over the last several months. The moratorium on high complexity and elected surgeries in Bogota ended in July. At this time, I'll ask Steve to go over the details of our financial results. Steve.

Thank you, Ed. This morning, we reported normalized FFO of $0.44 per diluted share for the third quarter of 2021, along with adjusted FFO per share of $0.34. From the end of 2019 through 2021, year-to-date. MPT is among a very small handful of large cap rates that continue to deliver double-digit growth on a per-share basis. When considered along with our low 80s% AFFO payout ratio, our access to abundant attractively priced capital and growing acquisition opportunities in virtually all of our markets. MPT offers near and long-term immediately accretive asset, revenue, and dividend growth that is not available for most regions. And that's exactly what the activities of the Third Quarter, so abundantly demonstrated. Before I discuss these activities, I will point out a few minor items that impacted our reported results. First, as is the case every quarter, we recognized a change in the market value of our investment in the securities of Aevis, the parent of our tenant, Swiss Medical Network, and $800,000 gain for this quarter. Second, we wrote off $3.6 million in straight line rent and other costs related to properties that were sold during the quarter for an aggregate of about $42 million. Aside from these routine reporting adjustments, we realized gains on these transactions of about $9.3 million. As we have previously explained, GAAP requires us to present as MPT expenses, certain cost, even though they are contractual obligations of and we are reimbursed by our tenants. These charges amounted to approximately $4 million for the quarter, and we included this amount in property-related expenses and offsetting revenue of a similar amount in our Income Statement. Finally, again as required by GAAP, we have reclassified the book value of the Massachusetts hospitals that are pending contribution to our joint venture with Macquarie to real estate held for sale on the Balance Sheet. So beginning with the July completion of our five Hospital $900 million expansion in the South Florida, I'll highlight the near and long-term importance of our recent transactions, which for the most part we have previously announced. The primary appeal of these South Florida hospitals is their long-standing historical and future important to various densely populated in growing communities with significant barriers to new development, and alternative healthcare facilities. Looking forward, we are excited about stewards plans to raise the bar for care in these facilities and improve their financial results to position them for long-term success. Importantly, as part of our agreements with Steward concerning these hospitals, Steward made early elections to extend our master lease agreement for all Steward Hospitals by 10 years to the year of 2041. It is important to view this exciting new acquisition in conjunction with the $1.78 billion Massachusetts joint venture with Macquarie and the $1.2 billion HCA re-tenanting of Steward Utah hospitals. Upon completion of these transactions, and completion is not assured, MPT will have access to approximately $1.3 billion in attractively priced capital, greatly diversified its tenant mix, introduced HCA as a top 5 tenant in the MPT portfolio of world-class hospital operators and creatively recycled JV proceeds into these irreplaceable hospital facilities in the country, seventh largest metropolitan area. I'll take a few minutes to review details of these to track transactions. And I will be happy to take questions in just a few minutes. On September 1, we announced an agreement by which a 50-50 partnership formed with a subsidiary of Macquarie Infrastructure Partners will purchase from MPT, 8 Massachusetts based -based general acute hospitals operated by Steward for approximately $1.78 billion. This is a portfolio that from being on the verge of closing in 2010, is now a coherent network of award-winning hospitals that has proven remarkably resilient in its delivery of care and its financial performance throughout our period of investment. MPT recognized in its underwriting prior to our initial investment in 2016, that the community serve truly dependent on these particular hospitals and that stewards operating model was likely to drive substantial value creation. And five-years later, after a substantial independent diligence process, Macquarie recognized this same dynamic, both in terms of the value of the real estate and in what Steward has created. Coincidentally and later in September, we announced an agreement to lease five hospitals in Utah currently operated by Steward to HCA Healthcare upon the closing of Steward's related planned sale to HCA of the hospital’s operations. In a manner similar to MPT's investment in the Massachusetts hospitals, in 2017, we underwrote these Utah hospitals to their full potential in the context of Stuart model. Actual cash flow not only created strong rent coverage, but facilitated MPT's ability to refinance its initial mortgage loan investment with a larger and much preferable sale leaseback structure, reflective of full market real estate value without compromising coverage. Fast-forward to today, HCA Healthcare, one of the premier hospital operators in the world, has agreed to rental payments and purchase obligations that validate the real estate values that MPT previously underwrote. Just a relevant reminder, since 2016, we have underwritten and invested $4.4 billion in 40 hospitals leased to Steward in six major and independent market areas. Over that period, we have been paid more than $1.2 billion in rent and interest and our shareholders have been rewarded with growing dividends and share value. The size, credit characteristics, and market diversification of this assembled portfolio is what allowed us during the third quarter to orchestrate the tremendous value enhancement represented by the Massachusetts and Utah transactions and the recycling into the Florida hospitals. So just to wrap up, our recent activities, last week we closed on our acquisition of 18 in-patient behavioral hospitals, master lease to Springstone across several U.S. states for a total of $760 million. These facilities are purpose-built behavioral hospitals in carefully selected communities and very well-run. A unique portfolio that we have been observing for several years. We also invested $190 million to own a 49% interest in the operator. Similar, but infrequent, OpCo investments we have made in the past have been extraordinarily successful. Because the level of investment is typically relatively small, the benefits are sometimes more about having competitive advantage -- advantages in a process being run to sell an Operator. Whose assets are heavily weighted toward hospital real estate than simply a nominal return. Nonetheless, our results are almost uniformly strongly profitable. Many of you will remember our double-digit IRRs from Ernest Health, Capella, now LifePoint and others. And just this month, we realize similar returns from the sale of our equity interest in Median Kliniken and separately in German acute care operator ATOS Clinics. While our investment in these operators were not material amount, we realized very attractive gains. More importantly, only because we were willing to underwrite and make these investments years ago, where we in a position to then acquire more than EUR1.5 billion in high quality hospital real estate, that we still own. When it comes to our investments in Steward and Swiss Medical among others, and now Springstone, which collectively represent a very small percentage of our overall investment base, we gain a great deal of alignment and insight. But an expectation for future capital gains is always part of our equation. I should also mention that we close in late October on an EUR18 million cancer treatment center in Portugal, lease to an affiliate of Health. This compliments our inaugural investment in Portugal in late 2019 and adds to our foothold in that nation's growing private healthcare market. And we remain active in and enthusiastic about Continental Europe, the United Kingdom, Australia, and South America. Finally, I will comment on both our current and proforma balance sheets. Funding for the Steward South Florida and Springstone investments was sourced with the combination of existing cash. As well as short-term borrowing resources, including a $1 billion interim line of credit, which we expect will be repaid in full upon completion of the announced Macquarie partnership. The resulting net debt to EBITDA ratio, taking all of this into account is expected to be 6.3 times. As we think about this ratio relative to our historical 5 to 6 times range, which is not changed, we remind investors that more than half of our investing activity since the end of 2018 has been outside of the U.S. And that in order to cost efficiently and naturally hedge, most of our related currency exposure and to take advantage of very attractive international debt markets. We have funded more than 75% of these international investments with non-U.S. dollar long-term unsecured debt at low rates. As evidenced by our recent EUR500 million unsecured notes offering at a coupon of less than 1%. Because of this and with no detriment to current liquidity, our net debt-to-EBITDA has temporarily and predictably fluctuated to levels outside our long-term target. Acquisitions in 2021 have been more heavily weighted to high quality U.S. facilities for which our history has generally been heavier use of equity funding. So we expect to see continued reduction in our leverage ratio. but in stark contrast to prior years, where follow-on equity was sometimes the only way to accomplish this, we now have more flexibility today with a vibrant, and growing direct investment market for infrastructure like hospitals with our ATM use. With the $22 billion Balance Sheet that provides opportunities for selective property sales, and with earnings retained over and above our low AFFO payout ratio. As a reminder, our run-rate guidance of $1.81 to $1.85 per diluted share is an estimate of the expected annual FFO for our in-place assets as of today, plus other assets that are either under-development or subject to bonding acquisition agreements. They are obviously not included in third-quarter results. These items, in addition to the impact of the announced Macquarie partnership and additional assumptions, assumptions related to reducing leverage to near six times, underpin our current guidance range. Beyond this, we assume no other investments or capital markets transactions and we'll plan to update the market in the future as they occur. The bedrock of our history of total shareholder return outperformance is the compounded effect of a well-covered dividend, as well as growth in per-share cash earnings. All within certain self-imposed and long-term parameters that keep our leverage very much in line with other healthcare reits. With that, I will turn the call back to the Operator for questions. Erika.

Your first question comes from Q - Jonathan Hughes with Raymond James.

Good morning. Thanks for the time. Edward K. Aldag, Jr: Good morning.

I know you are limited a bit in what you can say, but could you share some high-level commentary on the soon to be HCA Utah facilities and the option for you to sell them to HCA? I mean, could those effectively become like an ATM vehicle? Where if for some reason the future of the public market doesn't provide you with an attractive or appropriate cost of equity capital you could sell those to HCA to generate capital for other investments.

So that's a very good perspective. And it actually is the way if we were to elect that it could work. We -- I think in our announcement, we actually disclosed. There's a put option that we haven't disclosed, total details of it. But at a minimum that we can put the properties to HCA at no less than fair value. There's actually a flaw that we're unable to disclose, but it's a very attractive option for us and provides us the liquidity, flexibility that you just described.

Okay. And I assume that put option here is a unique feature to this deal because you don't have a meaningful equity stake in the operator unlike some of the other larger relationships you have.

Well, the put option is, is not normally something we have in our leases. I'm not sure that's necessarily related to less than 10% equity stakes in certain of our operators. But you're absolutely correct and that it's something of a unique feature.

Okay. And then one more for me. Looking at the other funding source to the debt side, your run rate net debt to EBITDA assumes six turns, but I think the pandemic in some recent actions proved your underwriting. It was well as the stability and safety of hospitals. And it's either you did talk about the leverage target in your prepared remarks. But as you consider running leverage, maybe a little higher like closer to 7 since it does seem like your hospitals can handle it, you can raise international pretty low rates. It just seems like an interesting way to lower your overall cost of capital and drive further accretion from investments. Just curious to hear your thoughts on that front.

Yeah, so going into fair observation, it's just to replicate from that perspective. At this point though, and for the long-term future, we think we'll retain that 5 to 6 times target. And there are good reasons for that were still growing very rapidly. We want to be able to react quickly to potential acquisition. Sometimes these are very large acquisitions. And if we're already running up towards the top of what is -- what does a prudent leverage range, then sometimes we don't have the flexibility to react quickly. So that's just one reason why we think the 5 to 6 times range is appropriate. Another is we are a public Company, there is a calculus, I'm not sure it can be precisely expressed, but there is a calculus between share value and leverage. And we think another reason for that 5 to 6 times is -- that's probably the fulcrum for keeping our equity valuation at a point where we think is appropriate.

Okay. Well, I appreciate the color, and thanks for the time.

Your next question comes from Jordan Sadler with KeyBanc Capital Markets.

Hey, this is Arthur Porto on for Jordan. My first question is on the investment pipeline through 2022, you could just provide some color on geography, asset type, and pricing and maybe the overall scale the pipeline? Edward K. Aldag, Jr: Sure, Arthur. The pipeline remains extremely strong. We continue to work a pipeline in the $3 to $5 billion range that doesn't mean we have three to $5 billion of acquisitions to make, but it's an active pipeline. But having said that, we haven't given any sort of indications of what we think will close for the remainder of the year. We've done 3.7 billion so far this year. We're very happy with where we are right now. The vast majority of that property of that pipeline is general acute care hospitals. located all throughout our existing markets. We've got some additional things that we know that we're working on with some of our existing operators, that will certainly come to fruition in the next couple of quarters. So that's where we are right now.

Great, thanks. And I just have a follow-up question on